{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:30:54Z","timestamp":1789093854615,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We explored effective therapeutic targets for systemic sclerosis (SSc) patients with high risk for pulmonary arterial hypertension (PAH) by plasma proteomics analysis. A total of fifty-seven patients with SSc were enrolled in the study and the prevalence of PAH was 19.3%. On the other hand, 75.4% of SSc patients showed the ratio of forced vital capacity percentage\/diffusing capacity of the lungs for carbon monoxide percentage&gt; 1.6 and met criteria for high risk of PAH. Identification of elevated plasma proteins in SSc patients with high risk of PAH, followed by upstream regulator analysis, predicted interleukin (IL)-17A as a major upstream molecule. Furthermore, we performed in vitro neutralization study using MT-6194, a bispecific antibody targeting both IL-17A and IL-6 receptor. We found that MT-6194 broadly suppressed the increased expression of downstream molecules of IL-17A including IL-17A-related cytokines\/chemokines, IL-17A-driven NF<jats:inline-formula><jats:tex-math>$$\\kappa$$<\/jats:tex-math><\/jats:inline-formula>B pathway and IL-6-driven JAK\/STAT pathway which were shown to be increased in SSc patients with high risk of PAH by the proteomics. Consequently, it is revealed that IL-17A is a promising target for early intervention in SSc patients with high risk for PAH.<\/jats:p>","DOI":"10.1038\/s41598-024-76987-6","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:38:26Z","timestamp":1732707506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interleukin-17A is a potential therapeutic target predicted by proteomics for systemic sclerosis patients at high risk of pulmonary arterial hypertension"],"prefix":"10.1038","volume":"14","author":[{"given":"Yuuichi","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Mogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"76987_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton, C. P. & Khanna, D. Systemic sclerosis. Lancet 390, 1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9 (2017).","journal-title":"Lancet"},{"key":"76987_CR2","doi-asserted-by":"publisher","first-page":"102211","DOI":"10.1016\/j.coph.2022.102211","volume":"64","author":"H Bukiri","year":"2022","unstructured":"Bukiri, H. & Volkmann, E. R. Current advances in the treatment of systemic sclerosis. Curr. Opin. Pharmacol. 64, 102211\u2013102211. https:\/\/doi.org\/10.1016\/j.coph.2022.102211 (2022).","journal-title":"Curr. Opin. Pharmacol."},{"key":"76987_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall, A. J. et al. Causes and risk factors for death in systemic sclerosis: a study from the eular scleroderma trials and research (eustar) database. Ann. Rheum. Dis. 69, 1809\u201315. https:\/\/doi.org\/10.1136\/ard.2009.114264 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"76987_CR4","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Primers 1, 15002. https:\/\/doi.org\/10.1038\/nrdp.2015.2 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"76987_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","volume":"15","author":"ER Volkmann","year":"2019","unstructured":"Volkmann, E. R. & Varga, J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat. Rev. Rheumatol. 15, 208\u2013224. https:\/\/doi.org\/10.1038\/s41584-019-0184-z (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"76987_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/acr.22121","volume":"66","author":"L Chung","year":"2014","unstructured":"Chung, L. et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res. (Hoboken) 66, 489\u201395. https:\/\/doi.org\/10.1002\/acr.22121 (2014).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"76987_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1183\/09059180.00005112","volume":"21","author":"M Humbert","year":"2012","unstructured":"Humbert, M., Gerry Coghlan, J. & Khanna, D. Early detection and management of pulmonary arterial hypertension. Eur. Respir. Rev. 21, 306\u2013312. https:\/\/doi.org\/10.1183\/09059180.00005112 (2012).","journal-title":"Eur. Respir. Rev."},{"key":"76987_CR8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1378\/chest.12-2396","volume":"144","author":"NF Chaisson","year":"2013","unstructured":"Chaisson, N. F. & Hassoun, P. M. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 144, 1346\u20131356. https:\/\/doi.org\/10.1378\/chest.12-2396 (2013).","journal-title":"Chest"},{"key":"76987_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13075-016-0933-1","volume":"18","author":"CR Pasarikovski","year":"2016","unstructured":"Pasarikovski, C. R. et al. Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. Arthritis Res. Ther. 18, 30. https:\/\/doi.org\/10.1186\/s13075-016-0933-1 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"76987_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan, J. G. et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the detect study. Ann. Rheum. Dis. 73, 1340\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203301 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"76987_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fphys.2018.00587","volume":"9","author":"B Odler","year":"2018","unstructured":"Odler, B. et al. Biomarkers for pulmonary vascular remodeling in systemic sclerosis: A pathophysiological approach. Front. Physiol. 9, 587. https:\/\/doi.org\/10.3389\/fphys.2018.00587 (2018).","journal-title":"Front. Physiol."},{"key":"76987_CR12","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/j.lpm.2014.06.007","volume":"43","author":"MA Gashouta","year":"2014","unstructured":"Gashouta, M. A., Humbert, M. & Hassoun, P. M. Update in systemic sclerosis-associated pulmonary arterial hypertension. Presse Med. 43, e293-304. https:\/\/doi.org\/10.1016\/j.lpm.2014.06.007 (2014).","journal-title":"Presse Med."},{"key":"76987_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.semarthrit.2014.03.002","volume":"44","author":"VM Hsu","year":"2014","unstructured":"Hsu, V. M. et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the pulmonary hypertension assessment and recognition of outcomes in scleroderma (pharos) cohort study. Semin. Arthritis Rheum. 44, 55\u201362. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.03.002 (2014).","journal-title":"Semin. Arthritis Rheum."},{"key":"76987_CR14","doi-asserted-by":"publisher","first-page":"156534","DOI":"10.1016\/j.cyto.2024.156534","volume":"176","author":"N Seki","year":"2024","unstructured":"Seki, N. et al. Th17\/il-17a axis is critical for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSC): SSC patients with high levels of serum il-17a exhibit reduced lung functions and increased prevalence of PAH. Cytokine 176, 156534. https:\/\/doi.org\/10.1016\/j.cyto.2024.156534 (2024).","journal-title":"Cytokine"},{"key":"76987_CR15","doi-asserted-by":"publisher","first-page":"9326","DOI":"10.1074\/jbc.M117.818559","volume":"293","author":"M Lyman","year":"2018","unstructured":"Lyman, M. et al. A bispecific antibody that targets il-6 receptor and il-17a for the potential therapy of patients with autoimmune and inflammatory diseases. J. Biol. Chem. 293, 9326\u20139334. https:\/\/doi.org\/10.1074\/jbc.M117.818559 (2018).","journal-title":"J. Biol. Chem."},{"key":"76987_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2011-200837","volume":"71","author":"M Manetti","year":"2012","unstructured":"Manetti, M. et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann. Rheum. Dis. 71, 1064\u201372. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200837 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"76987_CR17","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.2147\/JIR.S379815","volume":"16","author":"M Muruganandam","year":"2023","unstructured":"Muruganandam, M., Ariza-Hutchinson, A., Patel, R. A. & Sibbitt, J. W. L. Biomarkers in the pathogenesis, diagnosis, and treatment of systemic sclerosis. J. Inflamm. Res. 16, 4633\u20134660. https:\/\/doi.org\/10.2147\/JIR.S379815 (2023).","journal-title":"J. Inflamm. Res."},{"key":"76987_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/ard-2022-223237","volume":"82","author":"S Sanges","year":"2023","unstructured":"Sanges, S. et al. Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. Ann. Rheum. Dis. 82, 365\u2013373. https:\/\/doi.org\/10.1136\/ard-2022-223237 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"76987_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fmed.2018.00175","volume":"5","author":"PM Hickey","year":"2018","unstructured":"Hickey, P. M., Lawrie, A. & Condliffe, R. Circulating protein biomarkers in systemic sclerosis related pulmonary arterial hypertension: A review of published data. Front. Med. (Lausanne) 5, 175. https:\/\/doi.org\/10.3389\/fmed.2018.00175 (2018).","journal-title":"Front. Med. (Lausanne)"},{"key":"76987_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1378\/chest.10-0302","volume":"139","author":"CA Meadows","year":"2011","unstructured":"Meadows, C. A. et al. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest 139, 994\u20131002. https:\/\/doi.org\/10.1378\/chest.10-0302 (2011).","journal-title":"Chest"},{"key":"76987_CR21","doi-asserted-by":"publisher","first-page":"885609","DOI":"10.3389\/fimmu.2022.885609","volume":"13","author":"L Wei","year":"2022","unstructured":"Wei, L., Abraham, D. & Ong, V. The yin and yang of il-17 in systemic sclerosis. Front. Immunol. 13, 885609. https:\/\/doi.org\/10.3389\/fimmu.2022.885609 (2022).","journal-title":"Front. Immunol."},{"key":"76987_CR22","doi-asserted-by":"publisher","first-page":"e85032","DOI":"10.1371\/journal.pone.0085032","volume":"8","author":"X Xing","year":"2013","unstructured":"Xing, X. et al. Il-17a induces endothelial inflammation in systemic sclerosis via the erk signaling pathway. PLoS One 8, e85032. https:\/\/doi.org\/10.1371\/journal.pone.0085032 (2013).","journal-title":"PLoS One"},{"key":"76987_CR23","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1186\/s13075-014-0512-2","volume":"16","author":"M Liu","year":"2014","unstructured":"Liu, M., Yang, J., Xing, X., Cui, X. & Li, M. Interleukin-17a promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res. Ther. 16, 4223. https:\/\/doi.org\/10.1186\/s13075-014-0512-2 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"76987_CR24","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3389\/fimmu.2019.01726","volume":"10","author":"M Noack","year":"2019","unstructured":"Noack, M., Beringer, A. & Miossec, P. Additive or synergistic interactions between il-17a or il-17f and tnf or il-1beta depend on the cell type. Front. Immunol. 10, 1726. https:\/\/doi.org\/10.3389\/fimmu.2019.01726 (2019).","journal-title":"Front. Immunol."},{"key":"76987_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/2397198318808998","volume":"4","author":"N Giordano","year":"2019","unstructured":"Giordano, N. et al. Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the european society of cardiology and european respiratory society 2015 guidelines. J. Scleroderma Relat. Disord. 4, 35\u201342. https:\/\/doi.org\/10.1177\/2397198318808998 (2019).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"76987_CR26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna, D. et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 8, 963\u2013974. https:\/\/doi.org\/10.1016\/S2213-2600(20)30318-0 (2020).","journal-title":"Lancet Respir. Med."},{"key":"76987_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154631","author":"S Ebata","year":"2022","unstructured":"Ebata, S., Yoshizaki-Ogawa, A., Sato, S. & Yoshizaki, A. New era in systemic sclerosis treatment: Recently approved therapeutics. J. Clin. Med.[SPACE]https:\/\/doi.org\/10.3390\/jcm11154631 (2022).","journal-title":"J. Clin. Med."},{"key":"76987_CR28","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 65, 2737\u201347. https:\/\/doi.org\/10.1002\/art.38098 (2013).","journal-title":"Arthritis Rheum."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76987-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76987-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76987-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:04:02Z","timestamp":1732709042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76987-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76987"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76987-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29484"}}